TICKERNOMICS Sign up
Last Update: 2024-03-28 02:13:26
RIGEL PHARMACEUTICALS INC ( RIGL ) https://www.rigel.com
1.43USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
RIGL
4.78%
SPY
32.74%
-59.17%
RIGL
SPY
92.93%
-44.55%
RIGL
SPY
224.41%
-62.79%
RIGL
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
253.50
237.54
0.30
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-9.78
1.92
-8.85
-32.32
0.00
-9.25
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-15.87
95.49
-23.52
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.5524
-49.89
-26.85
0.88
Other Earnings and Cash Flow Stats:
RIGEL PHARMACEUTICALS INC ( RIGL ) Net Income TTM ($MM) is -38.99
RIGEL PHARMACEUTICALS INC ( RIGL ) Operating Income TTM ($MM) is -32.05
RIGEL PHARMACEUTICALS INC ( RIGL ) Owners' Earnings Annual ($MM) is -36.68
RIGEL PHARMACEUTICALS INC ( RIGL ) Current Price to Owners' Earnings ratio is -6.79
RIGEL PHARMACEUTICALS INC ( RIGL ) EBITDA TTM ($MM) is -30.61
RIGEL PHARMACEUTICALS INC ( RIGL ) EBITDA Margin is -23.52%
Capital Allocation:
RIGEL PHARMACEUTICALS INC ( RIGL ) has paid 0.00 dividends per share and bought back -2.41961 million shares in the past 12 months
RIGEL PHARMACEUTICALS INC ( RIGL ) has reduced its debt by 41.709 million USD in the last 12 months
Capital Structure:
RIGEL PHARMACEUTICALS INC ( RIGL ) Interest-bearing Debt ($MM) as of last quarter is 0
RIGEL PHARMACEUTICALS INC ( RIGL ) Annual Working Capital Investments ($MM) are 51
RIGEL PHARMACEUTICALS INC ( RIGL ) Book Value ($MM) as of last quarter is -29
RIGEL PHARMACEUTICALS INC ( RIGL ) Debt/Capital as of last quarter is -4%
Other Balance Sheet Stats:
RIGEL PHARMACEUTICALS INC ( RIGL ) has 32 million in cash on hand as of last quarter
RIGEL PHARMACEUTICALS INC ( RIGL ) has 53 million of liabilities due within 12 months, and long term debt 59 as of last quarter
RIGEL PHARMACEUTICALS INC ( RIGL ) has 174 common shares outstanding as of last quarter
RIGEL PHARMACEUTICALS INC ( RIGL ) has 0 million USD of preferred stock value
Academic Scores:
RIGEL PHARMACEUTICALS INC ( RIGL ) Altman Z-Score is -15.12 as of last quarter
RIGEL PHARMACEUTICALS INC ( RIGL ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
RIGEL PHARMACEUTICALS INC ( RIGL ) largest shareholder is Two Sigma Advisers, LLC owning 1031291 shares at 1.47 ($MM) value
Dean L Schorno(an insider) Sold 5389 shares of RIGEL PHARMACEUTICALS INC ( RIGL ) for the amount of $8945.74 on 2023-02-02
1.44% of RIGEL PHARMACEUTICALS INC ( RIGL ) is held by insiders, and 65.92% is held by institutions
RIGEL PHARMACEUTICALS INC ( RIGL ) went public on 2000-11-29
Other RIGEL PHARMACEUTICALS INC ( RIGL ) financial metrics:
FCF:-85.83
Unlevered Free Cash Flow:-131.01
EPS:-0.13
Operating Margin:-15.87
Gross Profit Margin:95.49
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:79.49
Beta:0.88
Buffet's Owners Earnings:-36.68
Price to Owner's Earnings:-6.79
About RIGEL PHARMACEUTICALS INC ( RIGL ) :
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase II/III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, the company's other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, it has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company was incorporated in 1996 and is headquartered in South San Francisco, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.